AFFY  Affymax Inc.

Exchange

NASDAQ

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

2.82M

Current Price

$0.08
-0.0064 (-7.8528%)

Book Price

$-0.21
Overvalued by 379.84%
Financial Institution

Company Metrics

  • P/E 0.9159
  • P/S 72.7502
  • P/B 0.5906
  • EPS 0.082
  • Dividend 0 / 0%
  • Avg. Vol. 66,713.00
  • Shares 37.55M
  • Market Cap. 2.82M

Company Description

Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood ... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a ...
Business Wire (press release) - Nov 26, 2014
CUPERTINO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (OTCQB: AFFY) today announced that its Board of Directors has declared a special cash distribution to shareholders in the amount of $0.05 per share.
Technical Insights on Affymax, Inc. (OTCMKTS: AFFY)
MicroCap Daily - Nov 3, 2014
Affymax, Inc. (OTCMKTS: AFFY) has been moving in a bearish trend since July, 2014 trading around $0.10 per share, but the stock did saw a major bullish rally in the months of January to April , 2014 when its touched its high of $1.04 at a trading ...
Affymax, Inc. (AFFY): Affymax Likely Worthless: Omontys Kills At Least 9x More ...
Seeking Alpha - Aug 28, 2013
Affymax, Inc. (OTCPK:AFFY) is a shell company that owns potential future royalty and milestone payments associated with the recently recalled drug Omontys (peginesatide).
Affymax, Inc. (AFFY): Affymax: Emerging Data Supports Conclusion Omontys ...
Seeking Alpha - Nov 12, 2013
After reviewing the summary adverse event report data highlighting a shocking number of deaths associated with Omontys, (discussed here), we followed-up with the FDA to request more information.
Affymax, Inc. (OTCMKTS:AFFY) Crashes After Losing Partner
HotStocked - Jun 17, 2014
Yesterday's market session was a real disaster for Affymax, Inc. (OTCMKTS:AFFY, AFFY message board). Once the 8-K announcing that the partnership AFFY had with Takeda has been terminated affected the market, the company lost 54.55% of its share ...
Delisting of Securities of Telestone Technologies Corp, Affymax, Inc., Exide ...
GlobeNewswire (press release) - Jul 18, 2013
NEW YORK, July 18, 2013 (GLOBE NEWSWIRE) -- The NASDAQ Stock Market announced today that it will delist the common stock of Telestone Technologies Corp.
The end for Affymax (AFFY)
Seeking Alpha - Jun 24, 2014
With no hope for a return to the market for Omontys, Affymax's (AFFY) BOD approves the liquidation and dissolution of the company, subject to shareholder approval.
Affymax Board Announces Decision to Dissolve the Company - Business Wire (press release)
Affymax Board Approves Dissolving Troubled Company - Genetic Engineering News
Affymax, Inc.'s Pain Becomes Amgen Inc.'s Gain
iStockAnalyst (press release) - Feb 25, 2013
(By Mani) Affymax, Inc. (NASDAQ: AFFY) announced a national voluntary recall of all lots of Omontys after reports of serious hypersensitivity reactions including anaphylaxis.
Affymax stock plunges 85 percent on drug recall - Reuters
Takeda, Affymax Recall Omontys Drug After `Serious' Reactions - Bloomberg
Affymax, Inc. (NASDAQ:AFFY) Stock Shoots Up
HotStocked - Aug 9, 2010
On Friday, one month after the last deep plunge of Affymax, Inc. (NASDAQ:AFFY, AFFY message board) stock, a completely different scenario proved investor willingness to support the shares' upward direction.
AFFYMAX INCORPORATED (OTCMKTS:AFFY) Shorted Shares Increased 8.12% After ...
fdanewsalert.com - Feb 12, 2016
Affymax, Inc. is a biopharmaceutical company. The company has a market cap of $2.93 million. The Company's product OMONTYS is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis.